# hepatocellular carcinoma (HCC) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 40435
- Completion tokens: 14428
- Reasoning tokens: 0
- Total tokens: 54863
- API requests reported: 3
- Elapsed seconds: 135.836
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: OpenAI

---
## Data-quality warning

The supplied survival statistics are technically suspicious and should not be treated as quantitatively reliable without re-analysis. All 100 selected genes have `P=0` and `FDR=0`; 97 are risk-associated and 3 are protective-associated. HRs are frequently identical or extreme, especially `5.1847055e+21` for many risk genes and `1.9287498e-22` for three protective genes. The ledger also reports 303 retained input rows, 100 unique genes, two duplicated genes/probes, and direction conflicts for `Y_RNA` and `Metazoa_SRP`.

This pattern is consistent with numerical underflow, complete or quasi-complete separation, overly sparse expression features, inappropriate handling of zeros, probe/gene duplication, or a failed survival-model pipeline. Therefore, the HR magnitudes and nominal significance cannot support definitive biological or prognostic conclusions. The interpretation below is explicitly **exploratory** and separates direct statistical evidence from external biological plausibility. **External statistical validation was not performed.**

## 1. Overall biological interpretation

The current table suggests an apparent, highly asymmetric OS association dominated by risk-associated features, with only three protective-associated features:

- **Risk-associated:** 97 genes, including `CGB2`, `SLC1A6`, `IRS4`, `CRH`, `OTX2`, `FOXI1`, multiple olfactory-receptor genes, small RNAs, pseudogenes, lncRNAs, and unmapped transcripts.
- **Protective-associated:** `CENPVL3`, `LOC105372753`, and `RP11-506K19.2`, each with `HR=1.9287498e-22`, `P=0`, and `FDR=0`.

Biologically, the selected genes do not form a conventional HCC prognostic signature centered on hepatocyte metabolism, cell-cycle activity, angiogenesis, hypoxia, immune infiltration, or extracellular matrix remodeling. Instead, they are dominated by poorly characterized transcripts, pseudogenes, repetitive/small-RNA annotations, olfactory-receptor-like genes, and a small number of genes associated with neuronal, endocrine, or amino-acid transport biology.

The most defensible interpretation is therefore that the analysis detected a **technical or composition-related feature pattern**, rather than establishing a coherent HCC survival mechanism. A possible exploratory signal involves ectopic or noncanonical expression of sensory GPCR-related genes, endocrine signaling, and amino-acid transport, but these hypotheses require independent expression and survival validation.

## 2. Core biological programs

### Program 1: Sensory GPCR and olfactory-receptor-like signaling

- **Association:** Apparent risk-associated.
- **Supporting genes:** `OR2M7`, `OR5T2`, `OR5M10`, `OR5M13P`, `OR5M5P`, `OR5M6P`, `OR11J6P`, `VN1R96P`.
- **Relevant standardized pathways/terms:**  
  - GO: **G protein-coupled receptor signaling pathway**  
  - GO: **detection of chemical stimulus involved in sensory perception of smell**  
  - Reactome: GPCR-related signaling would be the closest conceptual category, although a specific HCC pathway enrichment result was not supplied.
- **Interpretation:** Several selected genes belong to the same receptor family or receptor-like annotation space, and the retrieved ontology summary repeatedly links `OR2M7`, `OR5T2`, and `OR5M10` to membrane localization, sensory perception, and GPCR signaling. STRING records connect these three genes through `ARRB1`, `ARRB2`, `GNAL`, `GNB1`, and `GNG13`.
- **Evidence strength:** **Exploratory, program-level annotation support.** The dataset supplies a repeated risk direction, while pathway and network records provide biological plausibility.
- **Limitations:** The HRs are implausibly extreme and may reflect low-count or near-zero features. Olfactory-receptor transcripts in bulk liver tumor may represent rare cell populations, ambient RNA, cross-mapping, or annotation artifacts. The STRING relationships are network associations and do not establish that these receptors physically interact in HCC cells. No formal enrichment P value was supplied; pathway recurrence is not enrichment or replication.

### Program 2: Amino-acid/glutamate/aspartate transport

- **Association:** Apparent risk-associated, driven especially by `SLC1A6`.
- **Supporting genes:** `SLC1A6`; the batch ontology summary also included **L-aspartate import across plasma membrane** and **L-aspartate transmembrane transport**.
- **Relevant standardized pathways:**  
  - GO: **L-aspartate transmembrane transport**  
  - GO: **L-aspartate import across plasma membrane**  
  - Reactome: **SLC-mediated transport of amino acids** and **Glutamate Neurotransmitter Release Cycle**
- **Interpretation:** `SLC1A6` has `HR=5.1847055e+21`, `P=0`, and `FDR=0`, and external annotations identify it as a high-affinity glutamate/aspartate transporter. This could be consistent with altered amino-acid handling or a non-hepatocyte neural-like transcriptional component. However, the Reactome annotation primarily reflects the canonical neuronal function of the gene, not demonstrated activity in HCC.
- **Evidence strength:** **Supported hypothesis, but not an established HCC program.** Direct survival association is present in the uploaded table; pathway and tissue annotations support function, but not HCC-specific causality.
- **Limitations:** GTEx records show much higher `SLC1A6` expression in brain regions than in several non-neural tissues, making tissue contamination or unusual cell composition important alternatives. No tumor expression distribution, tumor purity adjustment, or independent HCC survival statistic was supplied.

### Program 3: Endocrine and G-protein-linked signaling

- **Association:** Apparent risk-associated.
- **Supporting genes:** `CRH`, `CGB2`, `IRS4`, and possibly the GPCR-associated genes above.
- **Relevant standardized pathways/terms:**  
  - GO: **regulation of glucagon secretion**  
  - KEGG terms supplied: **Type II diabetes mellitus** and **regulation of lipolysis in adipocytes**
- **Interpretation:** `CRH`, `CGB2`, and `IRS4` suggest endocrine or hormone-responsive signaling rather than a canonical hepatocellular differentiation program. `IRS4` may be compatible with insulin/IGF-related signaling, while `CRH` and `CGB2` are endocrine-associated transcripts. Their collective appearance could indicate neuroendocrine-like differentiation, ectopic transcription, or contamination by non-tumor cellular components.
- **Evidence strength:** **Exploratory hypothesis.** The direct dataset association is strong in a numerical sense but unreliable because of the degenerate statistics. Ontology/KEGG annotations are contextual and were not calculated as independent statistical evidence.
- **Limitations:** These genes are not sufficient to diagnose neuroendocrine differentiation. The supplied pathways are broad and may be driven by annotation overlap. No protein measurements, histology, immunophenotype, or HCC-specific literature evidence linking this exact gene set to OS was provided.

### Program 4: Regulatory, noncoding, pseudogene, and small-RNA signal

- **Association:** Predominantly apparent risk-associated, with three protective-associated features.
- **Supporting genes:** Numerous lncRNAs, pseudogenes, small RNAs, and unmapped transcripts, including `MIR182`, `Y_RNA`, `RPL5P21`, `SNAI1P1`, `HMGB3P27`, `NEK4P3`, `LINC01665`, and multiple `UNMAPPED_ENSEMBL` entries.
- **Relevant standardized pathways:** No single reliable GO, Reactome, or KEGG pathway can be assigned to this group.
- **Interpretation:** This pattern may reflect genuine regulatory RNA biology, but it is more immediately compatible with transcript annotation instability, low-abundance feature behavior, genomic mapping ambiguity, or batch/platform effects. `MIR182` and Y RNA have cancer-related literature context; for example, PMID **22790015** discusses `MIR182` in advanced ovarian carcinoma, and PMID **32423154** reviews Y RNA as potential cancer biomarkers. These publications do not constitute HCC OS validation.
- **Evidence strength:** **Insufficient evidence for a defined biological program.** The direct statistical pattern is present, but functional coherence is not demonstrated.
- **Limitations:** Most listed transcripts lack robust functional annotation, and some records have direction conflicts or unmapped identifiers. Pseudogene and small-RNA measurements are particularly vulnerable to multi-mapping and library-preparation effects.

### Program 5: Bulk-tissue composition or ectopic-cellular-state signal

- **Association:** Predominantly apparent risk-associated.
- **Supporting genes:** The combined occurrence of `SLC1A6`, `CRH`, `OTX2`, `FOXI1`, olfactory-receptor genes, `CGB2`, and multiple noncoding/repetitive transcripts.
- **Relevant standardized pathway:** No specific pathway should be assigned; this is a biological interpretation rather than a formal enrichment result.
- **Interpretation:** The gene combination is unusual for a pure hepatocyte-derived tumor signal and may indicate variable tumor purity, stromal or neural-like cell content, endocrine-like cells, vascular or immune composition, or technical contamination. This alternative may explain why many unrelated genes show nearly identical extreme HRs.
- **Evidence strength:** **Supported confounding hypothesis.** It is supported by the unusual gene composition and expression-context annotations, not by an independent statistical test.
- **Limitations:** Cell-type proportions, pathology review, tumor purity, and sample-level expression distributions were not supplied, so the source of the signal cannot be determined.

## 3. Key genes and interaction modules

Because the HR estimates are unreliable, these candidates should be considered **priorities for re-analysis and validation**, not confirmed prognostic biomarkers.

| Candidate | Current statistical result | Potential relevance | Relationship type and evidence |
|---|---|---|---|
| `SLC1A6` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Amino-acid/glutamate transport; possible metabolic or composition-related signal | STRING reports associations with `SLC1A1`, `SPTBN2`, `ARHGEF11`, `KAT5`, and `RORA`. These are **database network associations**, not proven direct physical interactions in HCC. |
| `OR2M7` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Sensory GPCR-like program | Pathway co-membership and STRING network association with `OR5T2`/`OR5M10` through `ARRB1`, `ARRB2`, `GNAL`, and `GNB1`; direct receptor-receptor interaction is **not established**. |
| `OR5T2` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Representative of the repeated olfactory-receptor pattern | Co-membership in sensory GPCR annotations and network association; not evidence of HCC-specific co-expression or causality. |
| `OR5M10` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Same sensory-receptor module | STRING-supported network association with `ARRB1`, `ARRB2`, `GNAL`, `GNB1`, and `GNG13`; relationship type should be treated as **putative/database-derived**. |
| `IRS4` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Insulin/IGF-associated adaptor signaling and endocrine biology | Functional pathway association; no direct interaction with the other selected genes was supplied. |
| `CRH` | Risk-associated; `HR=1510234.5`, `P=0`, `FDR=0` | Endocrine/neuroendocrine-like signaling hypothesis | Pathway co-membership and literature/annotation context; no direct physical or regulatory relationship to `CGB2` was established here. |
| `CGB2` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Hormone-associated or ectopic expression signal | STRING records include associations with `ABI2` and `ACTL7A`; these are **network associations**, not demonstrated physical interactions in liver tumor. |
| `MIR182` | Risk-associated; `HR=5.1847055e+21`, `P=0`, `FDR=0` | Candidate post-transcriptional regulatory marker | Literature supports cancer-related relevance in other contexts, including PMID **22790015** and PMID **31908034**, but not independent HCC OS replication. Specific target regulation was not supplied. |
| `Y_RNA` | Risk-associated representative row; `HR=5.1847055e+21`, `P=0`, `FDR=0`; ledger flags `direction-conflict; rows=168` | Potential RNA biomarker or technical/library signal | Literature discusses Y RNA as cancer and biomarker-related RNA, including PMID **32423154** and PMID **32944168**. The internal direction conflict makes this candidate unreliable until resolved. |
| `CENPVL3` / `LOC105372753` / `RP11-506K19.2` | Protective-associated; each `HR=1.9287498e-22`, `P=0`, `FDR=0` | Apparent protective cluster, but no coherent functional interpretation is supported | The identical extreme HRs suggest a model or numerical artifact rather than three independently confirmed protective mechanisms. **Insufficient evidence** for a protective interaction module. |

No direct physical interaction among the selected genes has been demonstrated by the supplied data. The strongest network pattern is the olfactory-receptor-associated STRING module, but it remains a mixture of pathway co-membership and database-derived association.

## 4. Validation priorities

### 1. Refit the survival analysis and test for numerical separation  
**Classification:** Confounding or composition check

- **Why prioritize:** The combination of `P=0`, `FDR=0`, HRs of `5.1847055e+21` and `1.9287498e-22`, and near-uniform risk direction makes model validity the immediate concern.
- **Current evidence:** All 100 genes are nominally significant, with 97 risk-associated and 3 protective-associated features; the ledger reports duplicate rows and two direction conflicts.
- **External evidence:** No independent-cohort statistic is available. Database annotations cannot validate the model.
- **Next step:** Recalculate from raw expression and survival data using verified event/censoring coding, log-transformed or normalized expression, filtering of near-zero prevalence features, duplicate-probe handling, penalized Cox or Firth regression, confidence intervals, Schoenfeld diagnostics, and permutation or bootstrap testing.
- **Status:** **Established evidence that technical re-analysis is required; biological conclusion remains exploratory.**

### 2. Determine whether the signal reflects tumor purity or cellular composition  
**Classification:** Confounding or composition check

- **Why prioritize:** Brain-/neural-associated `SLC1A6`, endocrine-associated `CRH`/`CGB2`, sensory receptors, and numerous low-characterization transcripts are atypical as a unified hepatocyte tumor program.
- **Current evidence:** `SLC1A6` is annotated for neurotransmitter and amino-acid transport and shows higher GTEx expression in brain regions; the selected gene set contains multiple receptor-like and ectopic transcripts.
- **External evidence:** GTEx tissue specificity and functional annotations support the possibility of non-hepatocyte or ectopic-cell contributions, but do not identify the source in HCC.
- **Next step:** Compare expression with tumor purity estimates, immune/stromal deconvolution, pathology review, single-cell or spatial transcriptomics, and matched adjacent liver. Validate representative transcripts by RNA in situ hybridization or targeted RT-qPCR.
- **Status:** **Supported hypothesis.**

### 3. Test the sensory GPCR module experimentally  
**Classification:** Mechanistic hypothesis / interaction-network hypothesis

- **Why prioritize:** `OR2M7`, `OR5T2`, and `OR5M10` recur in the ontology and STRING summaries and are all risk-associated in the supplied table.
- **Current evidence:** Each has `HR=5.1847055e+21`, `P=0`, and `FDR=0`; network records connect the group to `ARRB1`, `ARRB2`, `GNAL`, `GNB1`, and `GNG13`.
- **External evidence:** GO and STRING provide pathway/network plausibility, but do not establish expression in malignant hepatocytes, direct physical interaction, or survival causality.
- **Next step:** Confirm transcript identity and specificity by amplicon sequencing, assess protein expression, examine co-expression at the sample level, and perturb the receptor or downstream G-protein/arrestin pathway in authenticated HCC models.
- **Status:** **Exploratory hypothesis.**

### 4. Evaluate `SLC1A6` and amino-acid transport in HCC  
**Classification:** Mechanistic hypothesis / biomarker

- **Why prioritize:** It is one of the few protein-coding genes with a clear transporter annotation and belongs to a biologically interpretable metabolic program.
- **Current evidence:** Risk-associated `HR=5.1847055e+21`, `P=0`, and `FDR=0`; GO and Reactome support glutamate/aspartate transport.
- **External evidence:** QuickGO, Reactome, GTEx, and STRING support its canonical transporter biology. The cited literature record PMID **22424243** concerns glutamate transporter expression in brain tissue and schizophrenia, not HCC prognosis.
- **Next step:** Refit its association in a valid HCC cohort, adjust for stage, etiology, treatment, and purity, then measure transporter expression and glutamate/aspartate flux in tumor models.
- **Status:** **Supported biological hypothesis, not an established biomarker or therapeutic target.**

### 5. Assess noncoding and small-RNA features after annotation quality control  
**Classification:** Biomarker

- **Why prioritize:** `MIR182`, `Y_RNA`, lncRNAs, pseudogenes, and unmapped transcripts comprise a large fraction of the selected features, but are especially susceptible to mapping and library effects.
- **Current evidence:** Most are risk-associated with extreme HRs; `Y_RNA` has an internal direction conflict.
- **External evidence:** PMID **32423154** and PMID **32944168** support general cancer or biomarker relevance of Y RNA, while PMID **22790015** supports cancer-associated relevance of `MIR182` in ovarian carcinoma. These are not independent HCC OS statistics.
- **Next step:** Re-quantify using transcript-specific alignments, inspect multi-mapping and read coverage, verify mature RNA species, and test in an independent HCC cohort with prespecified models.
- **Status:** **Exploratory hypothesis.**

## 5. Evidence grounding and independence

- **Direct cohort evidence:** The only direct statistical evidence is the uploaded survival table. It reports the extreme HRs, `P=0`, `FDR=0`, and the risk/protective directions.
- **Pathway and ontology evidence:** The GO, KEGG, and Reactome records explain possible functions, including amino-acid transport, GPCR signaling, endocrine-related terms, and neuronal transport. These records are annotations, not newly calculated enrichment statistics.
- **Network evidence:** STRING associations support a receptor-centered network involving `ARRB1`, `ARRB2`, `GNAL`, `GNB1`, and `GNG13`, and transporter-related associations for `SLC1A6`. These relationships may combine physical, predicted, co-expression, and literature-derived evidence; they should not be interpreted uniformly as direct physical interactions.
- **Tissue/expression evidence:** GTEx supports tissue-context concerns, particularly for `SLC1A6`, but normal-tissue expression is not equivalent to tumor-cell expression.
- **Disease and clinical evidence:** The evidence pack reports disease/genetic/clinical records for all selected items, but record presence does not establish HCC OS association or causal involvement.
- **Literature evidence:** The supplied PubMed and Europe PMC records provide contextual support for `MIR182`, Y RNA, and glutamate-transporter biology. The cited studies are not independent validation of this HCC cohort.
- **Therapeutic evidence:** Therapeutic records exist for a minority of genes, but no supplied evidence demonstrates that any of these genes is an effective HCC treatment target. External source counts and database coverage are not evidence strength.

The annotation sources may overlap through common publications, pathway databases, or prediction models, so multiple records within one evidence class should not automatically be treated as independent confirmation.

## 6. Major limitations and alternative explanations

1. **Numerical or statistical failure:** Complete separation, zero-event strata, extreme coefficients, or underflow could produce the repeated HRs and zero P values. Refit the models before interpreting biology.
2. **Low-abundance and mapping artifacts:** Olfactory receptors, pseudogenes, small RNAs, and unmapped Ensembl features may be affected by multi-mapping, read-length limitations, or annotation-version problems. Inspect read-level alignment and feature prevalence.
3. **Tumor purity and cell composition:** Neural-like, endocrine-like, stromal, immune, or vascular components could generate apparent associations. Use purity estimates, deconvolution, pathology review, and single-cell/spatial data.
4. **Clinical confounding:** Stage, treatment, etiology, liver function, age, sex, and disease severity may correlate with both expression and OS. Multivariable Cox models and stratified analyses are required.
5. **Association does not imply causation or replication:** No independent-cohort statistic, calibrated confidence interval, or external HCC survival model was supplied. Pathway recurrence, literature plausibility, and database records cannot substitute for replication.

**Bottom line:** The table is best regarded as a technically unstable exploratory result that highlights possible sensory GPCR, amino-acid transport, endocrine-like, and noncoding-RNA signals, with `SLC1A6` and the `OR2M7`/`OR5T2`/`OR5M10` group as reasonable validation candidates. It does not currently establish a reliable HCC OS signature, a causal mechanism, a clinically useful biomarker, or an effective therapeutic target.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=36, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
